Reversible pulmonary hypertension in heart transplant candidates-pretransplant evaluation and outcome after orthotopic heart transplantation

• Published in: European journal of heart failure Vol. 5; no. 5; pp. 645 - 653
• Main Authors: Klotz, Stefan, Deng, Mario C., Hanafy, Dudy, Schmid, Christof, Stypmann, Jörg, Schmidt, Christoph, Hammel, Dieter, Scheld, Hans H.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.10.2003
• Subjects: Alprostadil - therapeutic use; Cardiac Catheterization; Case-Control Studies; Female; Heart Failure - mortality; Heart Failure - surgery; Heart Transplantation - mortality; Humans; Hypertension, Pulmonary - drug therapy; Male; Middle Aged; orthotopic heart transplantation; prostaglandin; pulmonary hypertension; Treatment Outcome; Vasodilator Agents - therapeutic use
• ISSN: 1388-9842; 1879-0844
• DOI: 10.1016/S1388-9842(03)00059-X

Background: Heart transplantation is the most effective treatment for well‐selected patients with endstage heart failure. Unfortunately, transplant candidates with pulmonary hypertension (PHT) are often not considered for heart transplantation. This study was performed to assess the value of prostaglandin E1 (PG‐E1) for reduction of PHT and to predict the postoperative outcome, compared to patients without PHT. Patients and methods: We studied a group of 151 consecutive heart transplant candidates using right heart catheterization. In patients with PHT (pulmonary vascular resistance, PVR≥2.5 Wood‐Units (WU) and/or transpulmonary gradient (TPG)≥12 mmHg) a short‐term treatment protocol with PG‐E1 was performed, to achieve PVR<2.5 WU and TPG<12 mmHg. Results: 61 patients (40%) had PHT according to our criteria. Reduction of PHT was successful in 71% of patients (n=43), of these, 18 patients underwent cardiac transplantation and the 1‐year mortality rate was 22% (n=4). The 1‐year mortality rate in transplanted patients without PHT was 14% (n=3). There was no statistical difference in survival between the PHT and the non‐PHT group. Outcome in patients without heart transplantation was similar in both groups, except for patients with non‐reducible PHT (1‐year mortality 50%). Conclusions: Our study demonstrates the efficacy and safety of PG‐E1 in lowering PHT in heart transplant candidates, as well as the need for aggressive evaluation and treatment in these patients. Patients with reversible PHT have comparable post‐transplant outcomes and no tendency to higher acute right ventricular failure.